Login / Signup

Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease.

S GengZ KuangP L PeissigD PageL MaursetterKaren E Hansen
Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2019)
We found that among individuals with stage 3 and 4 CKD, PTH was an independent predictor of fractures, vascular events, and death. Additional epidemiologic studies are needed to confirm these findings. If a target PTH range can be confirmed, then randomized placebo-controlled trials will be needed to confirm that treating HPT reduces the risk of fracture, vascular events, and death.
Keyphrases
  • chronic kidney disease
  • placebo controlled
  • double blind
  • end stage renal disease
  • phase iii
  • phase ii
  • open label
  • clinical trial
  • squamous cell carcinoma
  • radiation therapy
  • phase ii study